Mepenzolate bromide


Concise Prescribing Info
Indications/Uses
Adjunct in peptic ulcer.
Dosage/Direction for Use
Adult: PO 25-50 mg 4 times daily, titrated to the lowest effective dose and adjust accordingly to patient's response.
Administration
Should be taken with food.
Contraindications
Hypersentivity. Glaucoma, obstructive uropathy and GI disease, paralytic ileus, myasthenia gravis, unstable CV status in acute GI haemorrhage, intestinal atony, toxic megacolon complicating ulcerative colitis.
Special Precautions
Patient w/ autonomic neuropathy, ulcerative colitis, CV disease (e.g. coronary heart disease, CHF, cardiac arrhythmias, tachycardia, HTN), prostatic hypertrophy, hyperthyroidism. Renal and hepatic environment. Elderly, debilitated patients. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Drowsiness, blurred vision, diarrhoea, heat prostration, psyschosis. Nervous: Dizziness, headache, nervousness, confusion, insomnia, weakness. CV: Tachycardia, palpitations. GI: Vomiting, nausea, constipation, ageusia, bloating, xerostomia. Endocrine: Decreased lactation. Genitourinary: Urinary retention, urinary hesitancy, impotence. Ophthalmologic: Increased ocular tension, cycloplegia, mydriasis. Dermatologic: Urticaria, hypohidrosis.
Potentially Fatal: Anaphylaxis.
Drug Interactions
May increase adverse effects of other anticholinergic drugs (e.g. amantadine, class I antiarrhythmic agents, antihistamines, antipsychotic agents, benzodiazepines, MAOIs, narcotic analgesics, nitrates and nitrites, sympathomimetic agents, TCA). May antagonise effects of antiglaucoma agents and drugs which alter GI motility (e.g. metoclopramide). Increased serum digoxin concentration and toxicity.
Disclaimer: This information is independently developed by CIMS based on mepenzolate bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in